First Japanese Pharmaceutical Firm Eisai To Open Singapore Regional Clinical Research Centre

Eisai Clinical Research Singapore Pte Ltd is the first Japanese pharmaceutical company in Singapore to focus on integrative neuroscience and integrative oncology-related products.

With the company's growth progression, Eisai Global Clinical Development, the company's global unit for clinical development, was organised to centralise the management of global clinical development.

In order to respond to the recent clinical research growth of Asia, Oceania, and the Middle East (AOME), Eisai Global Clinical Development proposed the establishment of the Eisai Clinical Research Singapore Pte Ltd., seeking productivity and efficiency in clinical development in the region.

Eisai Clinical Research Singapore has taken the initial steps to strategically grow its clinical research operations in the region in order to achieve greater efficiency in bringing more new products into the region and global market.

The Asia Pacific region now accounts for almost 56% of the world's population, 25% of the world's GNP and 22% of the world's international trade.

Moreover, current trends indicate that the next centre of gravity for the global pharmaceutical market will be in Asia, with China, India and Singapore being the key countries.

Raymond Chua, managing director of Eisai Clinical Research Singapore said, "The Asia-Pacific and Middle East countries will play an increasing role in clinical research activities over the next 10 years, with the fast maturing regulatory environment, increasingly experienced investigators, higher data quality yield and growing patient base in these regions."

Some of the clinical trials that will be initiated in the Asia-Pacific region would include that of new oncology compounds for breast cancer, critical care compounds for severe sepsis, and neurology compounds for epilepsy and Parkinson's disease.